The proprietary chemistry technology at Wave Life Sciences is designed to create “stereopure” versions of RNA-based drugs that are more potent, safer, and longer-lasting than similar RNA drugs from other companies. On Monday, however, the Cambridge, Mass.-based biotech’s most crucial clinical test of its platform yielded very disappointing results.
In a study involving patients with Duchenne muscular dystrophy, 12 weeks of treatment with the Wave drug called suvodirsen failed to increase levels of dystrophin compared to baseline, the company said.
About the Author Reprints
